We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.76B
1-Year Est. Return 62.41%
This Fund
S&P 500
This Quarter Est. Return
+9.09%
1 Year Est. Return
+62.41%
3 Year Est. Return
+179.84%
5 Year Est. Return
+371.69%
10 Year Est. Return
+1,534.25%
AUM
$5.62B
AUM Growth
+$874M
Cap. Flow
+$401M
Cap. Flow %
7.12%
Top 10 Hldgs %
66.07%
Holding
710
New
128
Increased
146
Reduced
103
Closed
149
Avg Time Held Equity + Options
3.9 quarters
Top 10 Avg Time Held Equity + Options
1.5 quarters
Top 20 Avg Time Held Equity + Options
1.3 quarters
Avg Time Held Equity only
4.1 quarters
Top 10 Avg Time Held Equity only
1.5 quarters
Top 20 Avg Time Held Equity only
1.3 quarters

Top Buys

Rank Stock Value
1
ATVI
Activision Blizzard
ATVI
+$779M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$358M
3
NEWR
New Relic, Inc.
NEWR
+$258M
4
DEN
Denbury Inc.
DEN
+$175M
5
VMW
VMware, Inc
VMW
+$165M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$230M
2
PDCE
PDC Energy, Inc.
PDCE
+$221M
3
UNVR
Univar Solutions Inc.
UNVR
+$219M
4
FOCS
Focus Financial Partners Inc. Class A
FOCS
+$146M
5
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$141M

Sector Composition

Rank Sector Weight
1 Technology 39.86%
2 Healthcare 28.77%
3 Miscellaneous 7.24%
4 Real Estate 5.15%
5 Financials 4.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ADBE icon
351
Adobe
ADBE
$94.3B
$655K 0.01%
1,284
+251
+24% +$132K
2023 Q1
2 quarters
ITOS icon
352
DELISTED
iTeos Therapeutics
ITOS
$654K 0.01%
59,764
+8,000
+15% +$102K
2022 Q1
6 quarters
INZY icon
353
DELISTED
Inozyme Pharma
INZY
$652K 0.01%
155,305
– –
2022 Q2
5 quarters
EDIT icon
354
Editas Medicine
EDIT
$445M
$642K 0.01%
82,369
– –
2023 Q1
2 quarters
VKTX icon
355
Viking Therapeutics
VKTX
$3.63B
$641K 0.01%
57,905
+16,000
+38% +$229K
2022 Q3
4 quarters
AMLX icon
356
Amylyx Pharmaceuticals
AMLX
$3.53B
$641K 0.01%
35,000
-4,000
-10% -$84.6K
2023 Q2
1 quarter
AAL icon
357
American Airlines Group
AAL
$8.45B
$641K 0.01%
+50,000
New +$776K
2023 Q3
0 quarters
XIFR icon
358
PUT
XPLR Infrastructure LP
XIFR
$978M
$637K 0.01%
+140,000
New +$7.09M
2023 Q3
0 quarters
CRL icon
359
Charles River Laboratories
CRL
$14.4B
$629K 0.01%
3,211
– –
2022 Q4
3 quarters
TSLA icon
360
Tesla
TSLA
$1.51T
$626K 0.01%
2,500
-1,000
-29% -$257K
2021 Q2
9 quarters
ESPR icon
361
DELISTED
Esperion Therapeutics
ESPR
$619K 0.01%
631,947
+335,000
+113% +$485K
2022 Q3
4 quarters
HIW icon
362
Highwoods Properties
HIW
$3.2B
$618K 0.01%
30,000
-70,000
-70% -$1.66M
2023 Q1
2 quarters
HLN icon
363
Haleon
HLN
$41B
$618K 0.01%
74,185
-180,000
-71% -$1.5M
2022 Q3
4 quarters
GPCR icon
364
Structure Therapeutics
GPCR
$1.82B
$616K 0.01%
12,218
+2,025
+20% +$65.3K
2023 Q1
2 quarters
INBX icon
365
DELISTED
Inhibrx, Inc. Common Stock
INBX
$614K 0.01%
33,448
– –
2022 Q2
5 quarters
ELAN icon
366
Elanco Animal Health
ELAN
$11.5B
$609K 0.01%
54,176
– –
2022 Q4
3 quarters
PLTR icon
367
Palantir
PLTR
$502B
$600K 0.01%
37,500
+17,727
+90% +$282K
2023 Q2
1 quarter
EVLVW icon
368
DELISTED
Evolv Technologies Warrant
EVLVW
$600K 0.01%
693,200
– –
2021 Q3
8 quarters
QURE icon
369
uniQure
QURE
$1.57B
$597K 0.01%
88,965
-55,000
-38% -$495K
2022 Q4
3 quarters
MRK icon
370
Merck
MRK
$359B
$596K 0.01%
5,790
– –
2022 Q3
4 quarters
CRNX icon
371
CALL
DELISTED
Crinetics Pharmaceuticals
CRNX
$588K 0.01%
+60,000
New +$1.24M
2023 Q3
0 quarters
TRIP icon
372
TripAdvisor
TRIP
$1.02B
$580K 0.01%
35,000
– –
2023 Q1
2 quarters
F icon
373
PUT
Ford
F
$48.5B
$576K 0.01%
740,900
– –
2022 Q2
5 quarters
OVID icon
374
Ovid Therapeutics
OVID
$480M
$576K 0.01%
150,000
+20,000
+15% +$71.9K
2023 Q2
1 quarter
BGS icon
375
PUT
B&G Foods
BGS
$195M
$555K 0.01%
215,000
– –
2023 Q1
2 quarters
13 14
15
16 17

Similar funds

FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
ACI
Alpha Cubed Investments Irvine, California $2.92B AUM 31.27% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
A
AlphaQuest New York $1.79B AUM 10.61% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
CB
Cadence Bank Tupelo, Mississippi $1.71B AUM 16.17% 1-Year Est. Return
JCM
Janney Capital Management Pittsburgh, Pennsylvania $1.59B AUM 23.25% 1-Year Est. Return
MPM
Meritage Portfolio Management Overland Park, Kansas $1.51B AUM 26.61% 1-Year Est. Return

UBS O'Connor's Q3 2023 Portfolio in Review

As of Q3 2023, UBS O'Connor held 710 positions worth $5.62B, up 18% from $4.75B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

UBS O'Connor deployed $401M of net new capital in Q3 2023, opening 128 new positions and adding to 146 existing holdings. Its largest new stake was Denbury Inc.: 1,931,731 shares worth $189M.

By sector, the portfolio is most concentrated in Technology at 40% of assets, up from 16% a quarter earlier, followed by Healthcare and Miscellaneous.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $19.7M trimmed.

  • UBS O'Connor's largest Q3 2023 buy was Denbury Inc.: 1,931,731 shares worth $189M.
  • UBS O'Connor added most to Activision Blizzard in Q3 2023, an estimated $779M increase.
  • UBS O'Connor's biggest Q3 2023 reduction was Seagen Inc. Common Stock, cutting an estimated $19.7M.
  • UBS O'Connor fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $230M.
  • UBS O'Connor's ten largest holdings make up 66% of its $5.62B portfolio in Q3 2023.
  • UBS O'Connor opened 128 new positions and closed 149 in Q3 2023.
  • UBS O'Connor's portfolio value rose 18% quarter-over-quarter to $5.62B.

Based on UBS O'Connor's 13F filing for Q3 2023, filed 14 Nov 2023.